HIGHLIGHTS
- who: Hsp and collaborators from the University of Kansas Medical Center, United States have published the Article: Optimizing antidotal treatment with the oral HSP90 inhibitor TAS-116 against hydrochloric acid-induced pulmonary fi brosis in mice, in the Journal: (JOURNAL) of 15/03/2022
- what: The authors investigated the optimal dosing and windows of administration of TAS-116 against HCl-induced pulmonary fibrosis and chronic lung injury in mice. The authors used three different doses in search of the minimal effective dose against HCl-challenged animals showed a decrease in pressurevolume (PV) loops . The authors . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.